Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)

NCT00073450 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Squamous Cell
Head and Neck Neoplasms

Interventions

DRUG: Farnesyl Protein Transferase Inhibitor

Sponsor

Merck Sharp & Dohme LLC